MarketWatch EN

Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.

Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.

Mar 10, 2026 &03481010202631; 09:48 UTC feeds.marketwatch.com Trending 3/5

Read original on feeds.marketwatch.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Novo Nordisk faces a significant downgrade from TD Cowen as analysts warn that the company's duopoly position in diabetes and weight loss markets is deteriorating due to increasing competitive pressures. This threatens the company's premium valuation and future revenue growth prospects.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

Novo Nordisk

NVOStock

Expected to decline

Downgrade from TD Cowen citing erosion of duopoly competitive advantage in GLP-1 market

↓

Euro Stoxx 50

^STOXX50EIndex

Expected to decline

Novo Nordisk is a major STOXX 50 constituent; downgrade creates negative sentiment for European healthcare

⇅

DAX (Germany)

^GDAXIIndex

High volatility expected

Danish healthcare exposure through DAX-linked European equities

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing long positions in NVO or establishing short positions ahead of further downgrades. Monitor competitor announcements (Eli Lilly, Amgen) for market share gains that could accelerate Novo Nordisk's decline.

KEY SIGNALS

Duopoly market position under threatIncreased competitive pressure in GLP-1 marketValuation risk from market share erosionBroker downgrade signals analyst consensus shiftWeight loss and diabetes market competition intensifying

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 11, 2026 at 03:30 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by MarketWatch. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.

RELATED INTELLIGENCE